Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
79 hedge funds and large institutions have $107M invested in Agile Therapeutics in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 14 closing their positions.
209% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $497K
136% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 14
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
74% more capital invested
Capital invested by funds: $61.4M → $107M (+$45.5M)
30% more funds holding
Funds holding: 61 → 79 (+18)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.6M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.87M |
| 4 |
DCM
DG Capital Management
New York
|
+$1.47M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.23M |
| 2 |
Renaissance Technologies
New York
|
-$2.2M |
| 3 |
Millennium Management
New York
|
-$1.98M |
| 4 |
EP
Eversept Partners
New York
|
-$1.32M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.04M |
AGRX Hedge Fund Activity: Q2 2020 in Review
79 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2020, worth a combined $107M — up 74% from $61.4M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AGRX positions and 14 closed out — a net gain of 19 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $10.1M. The largest seller was OrbiMed, exiting entirely with an estimated $2.23M sold.
- 79 institutional investors held Agile Therapeutics (AGRX) as of Q2 2020, up from 61 in Q1 2020.
- Funds reported $107M of Agile Therapeutics stock for Q2 2020, up 74% quarter-over-quarter.
- 33 funds opened new Agile Therapeutics positions in Q2 2020 and 14 closed out, a net change of +19 holders.
- The largest Agile Therapeutics buyer in Q2 2020 was BlackRock, an estimated $10.1M added.
- The largest Agile Therapeutics seller in Q2 2020 was OrbiMed, an estimated $2.23M sold.
Based on aggregated 13F filings for Q2 2020.